Last reviewed · How we verify
Metastatic urothelial carcinoma
Approved treatments
- Balversa · xCures
- Enfortumab · Brigham and Women's Hospital
- Padcev · Astellas Pharma
Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction. - Enfortumab · Astellas Pharma
- Balversa · Johnson & Johnson
Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic urothelial carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic urothelial carcinoma treatment landscape brief
- Metastatic urothelial carcinoma treatment updates RSS
Frequently asked questions about Metastatic urothelial carcinoma
What drugs treat Metastatic urothelial carcinoma?
Tracked treatments include Balversa, Enfortumab, Padcev.
What is the treatment for Metastatic urothelial carcinoma?
Standard treatment for Metastatic urothelial carcinoma includes Balversa, Enfortumab, Padcev. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic urothelial carcinoma patent cliff · Metastatic urothelial carcinoma CI report
- Treatment: Balversa · xCures
- Treatment: Enfortumab · Brigham and Women's Hospital
- Treatment: Padcev · Astellas Pharma
- Treatment: Enfortumab · Astellas Pharma
- Treatment: Balversa · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing